Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Clene Inc. and its subsidiary Clene Nanomedicine Inc. are focused on revolutionizing treatments for neurodegenerative diseases such as ALS and MS [1][2] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference and host 1x1 investor meetings [1] Company Overview - Clene Inc. is a late clinical-stage biopharmaceutical company dedicated to improving mitochondrial health and protecting neuronal function [2] - The investigational therapy CNM-Au8 targets mitochondrial function and the NAD pathway, aiming to enhance the survival and function of central nervous system cells while reducing oxidative stress [2] - Clene is headquartered in Salt Lake City, Utah, with R&D and manufacturing operations located in Maryland [2]